Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Up to 15% of acute promyelocytic leukemia (APL) patients fail to achieve or maintain remission. We investigated a common G > A polymorphism at position -1377 (rs2234767) in the core promoter of the CD95 cell death receptor gene in 708 subjects with acute myeloid leukemia, including 231 patients with APL. Compared with the GG genotype, carrier status for the -1377A variant was associated with a significantly worse prognosis in APL patients. Carriers were more likely to fail remission induction (odds ratio = 4.22; 95% confidence interval, 1.41-12.6, P = .01), were more likely to die during the first 8 weeks of remission induction therapy (hazard ratio = 7.26; 95% confidence interval, 2.39-22.9, P = .0005), and had a significantly worse 5-year overall survival (odds ratio = 2.14; 95% confidence interval, 1.10-4.15, P = .03). The -1377A variant destroys a binding site for the SP1 transcriptional regulator and is associated with lower transcriptional activity of the CD95 promoter. Identifying patients at high risk of life-threatening events, such as remission induction failure, is a high priority in APL, especially because such events represent a major cause of death despite the introduction of differentiation therapy.

Original publication




Journal article



Publication Date





196 - 205


Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Apoptosis, Caspases, Cell Proliferation, Child, Child, Preschool, DNA, Neoplasm, Electrophoretic Mobility Shift Assay, Female, Genotype, Humans, Infant, Infant, Newborn, Leukemia, Promyelocytic, Acute, Luciferases, Male, Middle Aged, Polymerase Chain Reaction, Polymorphism, Genetic, Prognosis, Promoter Regions, Genetic, RNA, Small Interfering, Remission Induction, Sp1 Transcription Factor, Survival Rate, Tumor Cells, Cultured, Young Adult, fas Receptor